FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileEnliven Therapeutics, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ELVN
Enliven Therapeutics, Inc. Stock AnalysisComprehensive stock analysis for Enliven Therapeutics, Inc. (ELVN) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisELVN
ELVN
Enliven Therapeutics, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ELVN
  1. Home
  2. Stocks
  3. Enliven Therapeutics, Inc.

Enliven Therapeutics, Inc.

🇺🇸ELVN•NASDAQ

Enliven Therapeutics, Inc.

🇺🇸ELVN•NASDAQ
Market cap
$3.30B

Your view on ELVN

Mkt Cap
$3.30B
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Enliven Therapeutics, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Richard A. Fair
Headquarters
US
Industry
Biotechnology
Sector
Healthcare
CEO
Richard A. Fair
Headquarters
US
Description

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer.

Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Enliven Therapeutics, Inc.. Starting points for Enliven Therapeutics, Inc.: EPS -$1.46, beta 0.24 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Enliven Therapeutics, Inc.. Trailing twelve-month EPS for Enliven Therapeutics, Inc. stands at -$1.46. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 20, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Current price

—

live quote

Analysts' target

$76.29

average of 7 firms, last 12 months

 

$76.29

Low $70.00

Median $78.00

High $82.00

 

Analyst Ratings

Buy6 firms, last 12 months
  • Strong Buy0
  • Buy6
  • Hold0
  • Sell0
  • Strong Sell0

Earnings Estimate

EPSCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate−$0.44−$0.44−$1.68−$2.03
Low estimate−$0.58−$0.50−$2.02−$2.44
High estimate−$0.39−$0.41−$1.38−$1.82
No. of analysts6488
Year-ago EPS−$0.48−$0.38−$1.83—
Growth+7.6%−15.8%+8.5%—

Revenue Estimate

RevenueCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$0.00$0.00$10000.00$5000.00
Low estimate$0.00$0.00$10000.00$5000.00
High estimate$0.00$0.00$10000.00$5000.00
No. of analysts00510
Year-ago revenue$0.00$0.00$0.00—
Growth————
Recent analyst actions15 rating and price-target changes, latest Nov 6, 2026 — with the analyst, firm and source

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider; as of Nov 20, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Enliven Therapeutics, Inc.. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold ELVN20 companies · 8 funds
Compare ELVN with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustryMkt cap
AVBPArriVent BioPharma, Inc. Common StockHealthcareBiotechnology$563.8M
CGEMCullinan Therapeutics, Inc.HealthcareBiotechnology$584.9M
EXELExelixis, Inc.HealthcareBiotechnology$17.2B
INCYIncyte CorporationHealthcareBiotechnology$24.0B
NUVBNuvation Bio Inc.HealthcareBiotechnology$1.3B
ORICORIC Pharmaceuticals, Inc.HealthcareBiotechnology$795.1M
RLAYRelay Therapeutics, Inc.HealthcareBiotechnology$3.6B
RVMDRevolution Medicines, Inc.HealthcareBiotechnology$34.6B
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
RVXCFResverlogix Corp.HealthcareOTC$23.0M
RXRXRecursion Pharmaceuticals, Inc.HealthcareNASDAQ$1.8B
RYTMRhythm Pharmaceuticals, Inc.HealthcareNASDAQ$8.3B
RZLTRezolute, Inc.HealthcareNASDAQ$411.1M
SABSSAB Biotherapeutics, Inc.HealthcareNASDAQ$288.3M
SABSWSAB Biotherapeutics, Inc.HealthcareNASDAQ$10,514
SANASana Biotechnology, Inc.HealthcareNASDAQ$554.3M
SCNIScinai Immunotherapeutics Ltd.HealthcareNASDAQ$189,871
SCNLFScancell Holdings plcHealthcareOTC$189.4M
SCPSScopus BioPharma Inc.HealthcareOTC$16,833
SCPXScorpius Holdings, Inc.HealthcareOTC$130,071
SCTXScribe Therapeutics Inc.HealthcareNASDAQ$227.4M
ETFs holding Enliven Therapeutics, Inc.
TickerFundFund assets% of the fund
VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
IWMiShares Russell 2000 ETF$76.6B in assets0.10%
XSU.TOiShares U.S. Small Cap Index ETF (CAD-Hedged)$627M in assets0.10%
VXFVanguard Extended Market ETF$30.2B in assets0.03%
CANCTema Oncology ETF$215M in assets3.06%
XPHState Street SPDR S&P Pharmaceuticals ETF$516M in assets1.66%
IHEiShares US Pharmaceuticals ETF$1.7B in assets0.64%
DWASInvesco Dorsey Wright SmallCap Momentum ETF$376M in assets0.40%

Largest holders first, then the funds most concentrated in ELVN.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Enliven Therapeutics, Inc., and how their positions are changing. At a $3.30B market value, institutional positions materially move Enliven Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Enliven Therapeutics, Inc. executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Enliven Therapeutics, Inc.. Coverage tracks Enliven Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Enliven Therapeutics, Inc.

ELVN AnalysisFair
Past
5
Growth
2
Health
5
Profit
1
Value
1

News

Latest Market News